Evotec SE Share Price Other OTC
Equities
EVTCY
US30050E1055
Biotechnology & Medical Research
Sales 2024 * | 88Cr 95Cr 7.91TCr | Sales 2025 * | 103.77Cr 111.51Cr 9.3TCr | Capitalization | 130.04Cr 139.75Cr 12TCr |
---|---|---|---|---|---|
Net income 2024 * | -2.8Cr -3.01Cr -250.99Cr | Net income 2025 * | 3.1Cr 3.33Cr 277.88Cr | EV / Sales 2024 * | 1.73 x |
Net Debt 2024 * | 23Cr 24Cr 2.03TCr | Net Debt 2025 * | 19Cr 20Cr 1.67TCr | EV / Sales 2025 * | 1.43 x |
P/E ratio 2024 * |
-47
x | P/E ratio 2025 * |
27.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.64% |
Latest transcript on Evotec SE
Managers | Title | Age | Since |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 19/19/19 |
Laetitia Rouxel
DFI | Director of Finance/CFO | 51 | 07/23/07 |
Craig Johnstone
COO | Chief Operating Officer | 54 | 01/12/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 19/19/19 |
Roland Sackers
BRD | Director/Board Member | 56 | 19/19/19 |
Chairman | 63 | 17/14/17 |
1st Jan change | Capi. | |
---|---|---|
+34.01% | 5.11TCr | |
+33.84% | 3.89TCr | |
-8.02% | 3.88TCr | |
-8.98% | 2.67TCr | |
+12.56% | 2.63TCr | |
-19.62% | 1.95TCr | |
+39.18% | 1.36TCr | |
+31.47% | 1.25TCr | |
-3.40% | 1.17TCr |